PathomIQ Inc.

PathomIQ and Neuberg Diagnostics Partner to Deploy Novel AI-based Prognostic and Predictive Biomarker tests in Clinical Practice

by

CUPERTINO, Calif., June 6, 2023 /PRNewswire/ — PathomIQ INC. and Neuberg Diagnostics, today announced a multi-year partnership to accelerate clinical deployment of PATHOMIQ’s AI based prognostic and predictive biomarkers as a Lab Developed Test (LDT) which will be available in Neuberg Diagnostic’s laboratories worldwide to help advance precision medicine. PathomIQ is a leading provider of AI-enabled … Read more

PathomIQ’s AI-powered tool shows promise in assessing risk for metastasis in non-metastatic castration-resistant prostate cancer (nmCRPC)

by

CUPERTINO, Calif., June 6, 2023 /PRNewswire/ — New data released today at the American Society of Clinical Oncology (ASCO) Annual Meeting highlighted the application of PathomIQ Inc.’s PATHOMIQ_PRAD AI test to assess the risk for metastasis in non-metastatic castration-resistant prostate cancer (nmCRPC). PathomIQ is a leading provider of AI-enabled solutions that leverage digitized H&E slides … Read more